Artios collaborates with Novartis; Scholar Rock eyes Phase III trial; Novavax starts crossover arms in Covid-19 trials; Volastra nabs $44M
Apr 8, 2021
Artios Pharma announces collaboration with Novartis to tap next-generation DDR cancer therapies Artios Pharma Limited, a leading DNA Damage Response (DDR) company exploitin...
Read More
Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels
Apr 1, 2021
Amgen to acquire Rodeo Therapeutics for USD 55 Million Upfront Amgen Inc. and Rodeo Therapeutics Corporation announced a deal under which Amgen will take over Rodeo, ...
Read More
Asher Bio raises $55M; Roche halts Huntington’s phase 3 trial; Novartis’ radioligand hits goal in phase 3; EpimAb raises $120M in Series C
Mar 25, 2021
Asher Bio raises USD 55 Million in Series A financing Asher Biotherapeutics, a biotechnology company developing exactly targeted immunotherapies for cancer and other diseas...
Read More
GBT strikes a deal with Sanofi; Lilly’s IL-23 inhibitor shows promise; Glooko raises $30M; FDA uplifts hold on Solid’s DMD gene therapy
Mar 18, 2021
Global Blood Therapeutics strikes a deal with Sanofi for sickle cell disease programs As Global Blood Therapeutics works to bring its sickle cell disease drug, Oxbryta, to ...
Read More
Novavax targets COVID-19 approval; Iktos collaborates with Pfizer; AbbVie bags option to acquire Mitokinin; Presage inks new pact with Merck
Mar 4, 2021
Novavax targets approval for the COVID-19 vaccine in the US Novavax is targeting a second-quarter FDA filing for emergency use of its COVID-19 vaccine. The aim hints the U....
Read More
Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer
Feb 25, 2021
Beam adds to drug delivery stable with USD 120 Million GuideTx buy Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicin...
Read More
Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval
Feb 18, 2021
Bluebird suspends gene therapy trials after two sickle cell patients develop cancer Bluebird bio has stopped two clinical trials of its sickle cell disease gene therapy aft...
Read More
Verily – Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis
Feb 11, 2021
Verily collaborates with Janssen to launch COVID-19 immune response study Verily is partnering with Johnson & Johnson’s Janssen division to witness the body’s earli...
Read More
Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs
Feb 4, 2021
Plaque psoriasis drug outshines the competition in phase III trial Bristol Myers Squibb’s psoriasis drug, the TYK2 inhibitor outshone placebo and Amgen’s Otezla in a se...
Read More
Nirogy rises with $16.5M; Iterum presents a new drug application to FDA; Gut Bacteria proffer insight into molecules protection; TScan adds another $100M for cancer trials
Jan 28, 2021
Nirogy Therapeutics rises with USD 16.5 Million to target metabolite transporters Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small mo...
Read More
Unshackling TP53 in leukaemia with a novel combo; Merus receives funds for cancer research pact; Vera Therapeutics bags $80M; Gritstone appends COVID-19 to the pipeline.
Jan 21, 2021
Unshackling the TP53 in leukaemia with a novel combination approach. Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leuka...
Read More
Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate
Jan 14, 2021
Gilead and Vir Biotechnology Establish Clinical Collaboration Gilead Sciences, Inc. and Vir Biotechnology, Inc. announced that the companies have entered into a clini...
Read More
Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics
Jan 7, 2021
Ikena secures USD 120 Million to advance a growing pipeline of cancer drugs Ikena Oncology has bagged USD 120 million to develop its expanding pipeline of cancer drugs. The...
Read More
Improving cancer immunotherapy; Senseonics’ Eversense delayed; FDA acknowledges Alkermes’ Resubmission; 3D breast ultrasound improves diagnosis
Dec 31, 2020
Improving cancer immunotherapy by recovering a warning system Cancer cells, most of the time, develop tactics to elude the immune system. A research team that is led by sci...
Read More
NIH awards $107M for COVID-19 testing tech; GSK secures rights; Roche’s bispecific matches Eylea; Research Updates in Leukemia, solid tumors
Dec 24, 2020
NIH awards USD 107 Million for radical COVID-19 testing tech The National Institutes of Health (NIH) awarded over USD 107 million for radical approaches to testing fo...
Read More
